Snyders Pharmacy, located in Oregon’s Ace Hardware, announced it has suspended operation of its drive-thru due to lack of ...
The FTC study examines the practices of PBMs to ensure fair competition and transparency. The FTC found that from 2017 to 2022, the three big PBMs imposed substantial price markups on 51 specialty ...
The Federal Trade Commission accuses CVS, Cigna and UnitedHealth of artificially inflating prices on specialty generic drugs ...
The markups helped the PBMs reap $7.3 billion from 2017 to 2022, the FTC found. The PBMs—owned by insurers Cigna, CVS Health and UnitedHealth Group—are supposed to help keep drug costs low for ...
Claro Advisors LLC lessened its stake in shares of The Cigna Group (NYSE:CI – Free Report) by 35.9% during the fourth quarter ...
The practice inflated costs for consumers and insurers on key treatments for cancer, multiple sclerosis, HIV, organ transplants, and other conditions and procedures, the FTC said. The report ...
Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs ...
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...
Health-care companies slid after a profit warning from Eli Lilly. Shares of the obesity-drug maker tumbled after it slashed its projection for fourth-quarter revenue as the market for drugs that ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
The Federal Trade Commission accuses CVS, Cigna and UnitedHealth of artificially inflating prices on specialty generic drugs ...
The nation's three largest pharmacy benefit managers have significantly marked up the prices of certain medicines, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback